BioSpace News Archive

A group of leading scientists devoted to research on the mechanisms of biological aging announced the formation of the Academy for Health and Lifespan, the first global non-profit group focused on accelerating breakthroughs in the expansion of the human health span.

Genomma Lab will report Fourth Quarter 2018 results on Tuesday, February 26, 2019 after the Mexican Market close.

IBM Watson Health and the Broad Institute of MIT and Harvard are expanding their partnership to help clinicians better predict the possibility of serious cardiovascular diseases.

Initial projects focus on practical application of AI to improve care, enhance health team workflow, and better understand human-machine interactions

Safe Medical Design, Inc. announced that the U.S. Food and Drug Administration cleared the Signal Catheter™ for commercialization in the United States.

PTS Advance Acquires BioStaff Solutions and Moves into the Clinical Sector of Life Sciences

Goodwin Biotechnology Inc. (GBI) is a US-based, GMP contract development and manufacturing organization (CDMO) that offers cell line development, process development, cGMP contract manufacturing, and aseptic fill/finish of mammalian cell-culture derived monoclonal antibodies, recombinant proteins, vaccines, and antibody drug conjugates (ADCs) for early- and late-stage clinical trials.

The global interferons market is expected to post a CAGR of close to 2% during the period 2019-2023, according to the latest market research report by Technavio.

Ergomed plc (LSE: ERGO) (‘Ergomed’ or ‘the Company’), a company focused on providing specialised services to the pharmaceutical industry, announces that Stuart Jackson, Chief Financial Officer and Board Director has indicated that he will leave the Company in the Summer of 2019 to take up a position as Chief Financial Officer of a listed entity, returning to the energy sector.

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, and its private, wholly-owned subsidiary Centurion BioPharma Corporation, today announced the publication of peer reviewed, scientific research for LADR-7 (AE-Keto-Sulf07), one of its lead LADR™ (Linker Activated Drug Release) candidates.